Rune Labs, a San Francisco, CA-based brain data company enabling the advancement and delivery of precision neuroscience therapeutics, raised $22.8m in Series A financing.
The round was led by Eclipse Ventures with participation from current investors including DigiTx Partners and Moment Ventures. In conjunction with the funding, Justin Butler, Partner at Eclipse, will join the Rune Labs Board of Directors.
The financing will enable the company to expand the number of patients, clinicians, and researchers using its platform.
Led by Brian Pepin, founder and CEO, Rune Labs is empowering the development of precision medicines for Parkinson’s disease, multiple sclerosis, depression and other neurodegenerative disorders by using its software platform to make brain data useful at scale. Rune’s precision brain data software platform integrates electrophysiology, brain imaging, and device data together with wearable data and clinical labels. The combination will provide researchers, drug developers, and clinicians with the tools to guide treatment, uncover hidden disease phenotypes, and design targeted therapies.
The company partners with academic collaborators to optimize clinical care for patients and with biopharma and medtech companies to enable the development of targeted treatments for patients with brain diseases.